BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman Sells 588 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 588 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $20.74, for a total value of $12,195.12. Following the completion of the transaction, the chief financial officer directly owned 220,649 shares in the company, valued at approximately $4,576,260.26. This trade represents a 0.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, January 6th, Troy Wichterman sold 990 shares of BioLife Solutions stock. The shares were sold at an average price of $25.59, for a total transaction of $25,334.10.
• On Tuesday, December 9th, Troy Wichterman sold 1,033 shares of BioLife Solutions stock. The stock was sold at an average price of $25.13, for a total transaction of $25,959.29.

BioLife Solutions Stock Down 2.5%

BLFS traded down $0.51 during midday trading on Friday, hitting $19.61. The company had a trading volume of 184,806 shares, compared to its average volume of 403,503. The stock’s 50 day moving average price is $23.47 and its 200 day moving average price is $25.10. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.62. The company has a market capitalization of $947.16 million, a price-to-earnings ratio of -178.26 and a beta of 1.90.

Key Headlines Impacting BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview piece says BioLife has executed a successful turnaround, is refocused on core biopreservation media and vials, and forecasts FY2026 revenue growth of ~17–20%, positive GAAP net income and mid?60s gross margins; strategic moves (PanTHERA acquisition, QKine partnership) are expected to expand ARPU and enable next?gen product launches by late?2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release reiterates growth and strategic refocus — supports the turnaround narrative and management’s guidance to investors. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Short?interest data reported as zero shares (days?to?cover 0.0) — the figures appear erroneous or non?informative, so there is no clear evidence of elevated short pressure right now. MarketBeat BLFS
• Negative Sentiment: Several executives (CMO, CFO, EVP, CTO and others) filed small open?market sales (hundreds of shares each at ?$20.74). The amounts are modest relative to their holdings, but clustered insider sales can create near?term bearish sentiment. Insider filings / MarketBeat

Analysts Set New Price Targets

BLFS has been the subject of several recent research reports. Northland Securities set a $34.00 price objective on BioLife Solutions in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $32.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLFS. T. Rowe Price Investment Management Inc. boosted its stake in shares of BioLife Solutions by 27.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock worth $125,273,000 after buying an additional 1,113,972 shares during the last quarter. Capricorn Fund Managers Ltd purchased a new position in BioLife Solutions in the fourth quarter worth $9,153,000. Invesco Ltd. grew its stake in BioLife Solutions by 9.2% in the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after purchasing an additional 332,747 shares during the period. Qube Research & Technologies Ltd increased its position in shares of BioLife Solutions by 2,399.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after purchasing an additional 238,533 shares during the last quarter. Finally, Heights Point Management LP bought a new stake in shares of BioLife Solutions during the 4th quarter worth $5,260,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.